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BMIAbstract Aim of the work: This study was designed to measure the serum leptin level in patients
with rheumatoid arthritis, and to correlate it with clinical manifestations and disease activity.
Patients and methods: Sixty adult RA patients (58 females and 2 males) and 30 healthy subjects
matching age serving as the control group, were included in this study. Assessment of disease activ-
ity was done using the DAS-28 scoring system. Calculation of body mass index (BMI) was carried
out for both RA patients and controls. Measurement of the serum leptin level in RA patients and
controls was done using the DRG leptin ELISA Kit.
Results: RA patients showed statistically signiﬁcant higher mean serum leptin level than healthy
controls (24.86 ± 26.41 versus 10.73 ± 8.19 ng/dl respectively, P= 0.004). In addition, serum lep-
tin level showed a statistically signiﬁcant positive correlation with body mass index (P< 0.001). No
signiﬁcant correlation was found between serum leptin level and patients’ age, disease duration and
disease activity. Mean serum leptin level was 25.2 ng/ml in seropositive patients and 24.5 ng/ml in
seronegative patients, a ﬁnding which proved to be statistically signiﬁcant when comparing the two
groups (P= 0.004).
Conclusions: Even though serum leptin level was signiﬁcantly higher in the RA patients than in
the control group, no correlation was found between leptin level and clinical and laboratory param-
eters of disease activity. However the serum leptin level positively correlated with BMI in the RA
patients.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory systemic
disorder that is characterized by polyarthritis with often pro-
gressive joint damage and disability, immunologic abnormali-
ties, increased comorbidity, and premature mortality [1].
Rheumatoid arthritis is characterized by high concentrations
of pro-inﬂammatory cytokines, such as tumour necrosis
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The excessive production of inﬂammatory cytokines correlates
not only with joint disease activity and progression, but
also with a loss of body cell mass, known as rheumatoid
cachexia [2].
Leptin is a 16-kilo dalton (kDa) weight, non glycosylated
cytokine-like hormone synthesized almost exclusively by white
adipose tissue. Leptin and its receptors (Ob-R) share structural
and functional similarities with cytokines of IL-6 family and
their receptors. Leptin acts as a negative feedback signal for
neurons in the central nervous system (CNS) to decrease food
intake and to increase energy expenditure. Peripheral functions
of leptin include regulation of endocrine function, reproduc-
tion and immunity [3].
During acute inﬂammation, pro-inﬂammatory cytokines in-
crease circulating leptin concentration, and leptin, in turn,
potentiates cytokine release from monocytes/macrophages.
In addition, leptin stimulates T-cell mediated immunity and
is able to induce the proliferation and differentiation of
haemopoietic cells. The involvement of leptin in regulating
immune function in humans is strongly sustained by the
increased incidence of severe infection in subjects with genetic
leptin deﬁciency and by the deﬁciencies of the immune system
during starvation and malnutrition, when concentrations of
leptin are low [4].
Interactions between the neuroendocrine and immune sys-
tems contribute to the pathogenesis of RA. Among the differ-
ent neuroendocrine mediators, leptin plays a major role in the
pathogenesis of RA. Leptin, as an adipocytokine with pleiotro-
pic actions, may inﬂuence the inﬂammatory mechanisms of
arthritis in humans through the induction of T helper1 re-
sponses [5]. The aim of this study was to measure the serum
leptin level in patients with RA, and to correlate it with clinical
manifestations and disease activity.
2. Patients and methods
This study comprised sixty adult rheumatoid arthritis patients
(58 females and 2 males). They were all randomly selected
from the Rheumatology and Rehabilitation outpatient clinic
of El-Mataria Teaching Hospital. Patients were diagnosed
according to the 1987 revised American Rheumatism Associa-
tion Criteria for the classiﬁcation of rheumatoid arthritis [6].
Rheumatoid factor was positive in 25 (41.7%) patients. Thirty
healthy subjects of matching age to the patients served as the
control group. Patients suffering from diabetes mellitus and
those taking medication known to affect nutritional status or
regulation of fat metabolism were excluded from this study.
We followed our committee’s ethical guidelines in Cairo
University and an informed consent was obtained from all
subjects according to the Declaration of Helsinki; General
Assembly, October 2008.
Patients were subjected to full history taking, clinical exam-
ination, laboratory and radiological investigations necessary
for the diagnosis of rheumatoid arthritis. BMI was calculated
for all subjects [7] and DAS-28 score was used to assess the dis-
ease activity [8].
Measurement of the serum leptin level was done using the
DRG leptin ELISA kit [9]. The DRG leptin ELISA Kit is a so-
lid phase enzyme-linked immunosorbent assay (ELISA) based
on the sandwich principle. The microtitre wells are coated witha monoclonal antibody directed towards a unique antigenic
site on a leptin molecule. An aliquot of a patient sample con-
taining endogenous leptin is incubated in the coated well with
a speciﬁc rabbit anti-leptin antibody. A sandwich complex is
formed. After incubation, the unbound material is washed
off and an anti rabbit peroxidase conjugate is added for detec-
tion of the bound leptin. Having added the substrate solution,
the intensity of colour developed is proportional to the concen-
tration of leptin in the patient sample.
Statistics: Statistical presentation and analysis were con-
ducted by SPSS version 17. Numerical measures were repre-
sented as means and standard deviation. Cross tabulation
was utilized to describe the relations between variables using
the contingency coefﬁcient. Unpaired Student t-test was used
to compare between two groups in quantitative data. Mann–
Whitney was used to test the statistical difference between
the RA patients and controls regarding the serum leptin level.
Linear correlation coefﬁcient (r) was used for the detection of
correlation between two quantitative variables in one group. P
value <0.05 was considered signiﬁcant.
3. Results
The age of the sixty adult rheumatoid arthritis patients [58 fe-
males (96.7%) and 2 males (3.3%)] ranged between 25 and
55 years with a mean of 40.81 ± 9.11 years. Disease duration
ranged between 6 months and 20 years with a mean of
5.48 ± 4.15 years. Thirty healthy subjects (25 females and 5
males), of matching age to the patients, served as the control
group.
The clinical data of the RA patients are shown in (Table 1).
The DAS-28 score ranged between 2.8 and 8.50 with a
mean of 5.37 ± 1.11. Low disease activity <3.6 was found
in 5 (8.33%) patients, moderate disease activity P3.6–65.5
was found in 32 (53.33%) patients and high disease activity
>5.5 was found in 23 (38.33%) patients.
The laboratory data of the RA patients are shown in
(Table 2). Rheumatoid factor results are shown in (Table 3).
A signiﬁcant positive correlation was found between serum
leptin level and BMI (P< 0.001) in RA patients. However,
no signiﬁcant correlation was found between mean serum
leptin level and patients’ age (P= 0.72) and disease duration
(P= 0.51).
As regards RA activity, serum leptin level did not signiﬁ-
cantly differ in patients with low, moderate or high disease
activity (P= 0.86). Mean serum leptin level in patients with
low disease activity was 34.68 ± 48.37 compared to
22.21 ± 15.80 in patients with moderate disease activity and
26.41 ± 32.54 in patients with high disease activity (Table 4).
No signiﬁcant correlation was found between serum leptin
level and disease activity in the RA patients (Fig. 1).
Serum leptin level in RA patients ranged between 1.10 and
122.70 ng/ml with a mean of 24.86 ± 26.41. Serum leptin level
in control subjects ranged between 0.40 and 28 ng/ml with a
mean of 10.73 ± 8.19. A statistically signiﬁcant difference was
found between RA patients and controls as regards the serum
leptin level (P= 0.004). Patients with RA showed higher con-
centrations of leptin (almost twice the mean leptin levels) when
compared to the control group (24.86 ± 26.41 versus
10.73 ± 8.19 ng/dl respectively) (Table 5). However, they
did not differ signiﬁcantly with respect to BMI (P= 0.4). Mean
Table 1 Clinical data of the RA patients.
Clinical data Range Mean ± SD
Age (years) 25–55 40.81 ± 9.11
Disease duration (years) 6 months–20 years 5.48 ± 4.15
Morning stiﬀness duration (min) 60–180 87.97 ± 29.86
Tender joint count 2–28 11.9 ± 6.99
Swollen joint count 1–26 5.87 ± 6.08
Body mass index (kg/m2) 16–50 33.08 ± 7.98
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Figure 1 Scatter diagram showing the correlation between serum
leptin level and DAS-28 score in the RA patients with low,
moderate and high disease activity.
Table 2 Laboratory data of the RA patients.
Laboratory data Range Mean ± SD
ESR (mm/1st h) 15–110 44.5 ± 18.9
Hb (gm/dl) 9.5–13.6 11.15 ± 1.46
WBC count/mm3 4.3–10.8 7.65 ± 1.79
Platelet count/mm3 205–233.3 533 ± 730.01
Serum ALT (u/l) 9–39 19.42 ± 9.19
Creatinine (mg/dl) 0.5–1.2 0.74 ± 0.15
Serum leptin (ng/ml) 1.1–122.7 24.86 ± 26.41
Table 4 Comparison between mean serum leptin level and
RA patients with low, moderate and high disease activity.
DAS-28 Serum leptin Kruskal–Wallis test
Range Mean ± SD X2 P-value
Low 5.3–120.8 34.68 ± 48.37
Moderate 1.1–3 22.21 ± 15.8 0.30 0.86
High 3.2–122.7 26.41 ± 32.54
Table 3 Rheumatoid factor results in the RA patients.
RF RA patients
Number Percentage
Negative 25 58.3
Positive 35 41.7
Serum Leptin levels in Rheumatoid arthritis and relationship with disease activity 3BMI of RA patients was 33.08 ± 7.98 and that of controls was
31.76 ± 4.39.
A signiﬁcant difference was found between RA patients
with positive rheumatoid factor and those with negative rheu-
matoid factor as regards the serum leptin level (P= 0.004).
Mean serum leptin level of seropositive patients was
25.27 ± 27.16 ng/ml and that of seronegative patients was
24.57 ± 426.26 ng/ml (Table 6).
4. Discussion
RA is a chronic inﬂammatory disease that affects articular as
well as extra-articular structures. It is characterized by synovial
hyperplasia, inﬂammatory cell recruitment and in its later
stages cartilage and bone destruction. Several studies have
demonstrated that Th1/Th2 balance plays an important role
in RA, with Th1 and Th2 cytokines exerting pro-inﬂammatory
and anti-inﬂammatory effects [10].
Leptin was initially described as a hormone that regulates
food intake and energy balance. Later, it became apparent that
leptin has an important role in regulating neuroendocrine and
immune functions. Leptin and its receptors (Ob-R) share struc-
tural and functional similarities with cytokines of the interleu-
kin-6 family and their receptors [4].
Leptin activates monocyte/macrophage cells and increases
production of the pro-inﬂammatory cytokines (TNF-a and
IL-6). Leptin also stimulates the proliferation of T-cells, directs
T cell differentiation to Th1 phenotype and protects T-cells
from corticosteroid- induced apoptosis [11]. Leptin also exerts
anti-inﬂammatory activities, which are attributed to increased
IL-4 production and release of IL-1 receptor antagonist [12].
Fasting patients with RA exhibit an improvement in clinical
parameters of disease activity, associated with a decrease in
serum leptin concentration and a shift towards Th2 cytokine
production. These changes observed in RA patients and
experimental models suggest, that leptin may play a role in
inﬂammatory mechanisms of arthritis [13].
This study was designed to measure the serum leptin
level in patients with RA, and to correlate it with clinicalTable 5 Comparison between RA patients and controls
regarding mean serum leptin level.
Group Serum leptin Mann–Whitney test
Range Mean ± SD Z P-value
RA patients 1.10–122.70 24.86 ± 26.41 2.87 0.004a
Controls 0.40–28.00 10.7 ± 38.19
a Signiﬁcant.
Table 6 Comparison between seropositive and seronegative
RA patients as regards serum leptin level.
RF Serum leptin Mann–Whitney test
Range Mean ± SD Z P-value
Negative 2.10–120.80 24.57 ± 426.2625 2.876 0.004a
Positive 1.10–122.70 25.276 ± 27.1679
a Signiﬁcant.
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ducted on 60 RA patients (58 females and 2 males) and 30
healthy subjects of matching age to the patients.
In our study, no signiﬁcant correlation was found between
plasma leptin level and the age of RA patients (P= 0.72), or
disease duration (P= 0.51). Our results come in agreement
with the results of Popa and associates [4] who found that ser-
um leptin levels in RA patients were not related to disease dura-
tion. However, Bokarewa and colleagues [14] showed a gradual
increase of leptin concentration with the duration of RA.
A signiﬁcant difference was found between serum leptin le-
vel of the studied RA patients and controls. Serum leptin level
in patients with RA was signiﬁcantly higher than in healthy
controls (P= 0.004). This comes in agreement with Sarraf
et al. [15] who mentioned that in the process of chronic inﬂam-
matory diseases, pro-inﬂammatory cytokines (IL-1 and TNF-a)
increase obese gene expression and leptin secretion. Also, in
other studies [14,16–18], the serum leptin level was signiﬁcantly
higher in RA patients than controls. In a study by Otero and
associates [5] considerable higher plasma levels of fat derived
hormones (leptin, adiponectin and visfatin) were found in
RA patients than in healthy controls. Seven and colleagues
[19] found that serum and synovial ﬂuid leptin levels were sig-
niﬁcantly higher in RA patients than the control groups.
On the contrary, Targojska-Stdpniak and colleagues [20]
found that mean serum leptin concentration in their RA pa-
tients remained within normal ranges. Also, Bruun and
coworkers [21] considered that long-term stimulation of adi-
pose tissue by TNF-a or IL-1 inhibits leptin and leptin mRNA
production. Harle and associates [22] found almost three times
lower serum leptin concentration in a group of RA women
compared to the healthy women group. Tokarczyk-Knapik
and colleagues [23] suggested that chronic inﬂammation may
lower the leptin level in plasma concentration contrary to acute
inﬂammation. Nishiya and associates [24] found no difference
in the serum leptin between RA patients and controls. In
agreement, Popa and Associates [4] found that serum levels
of leptin were not increased in patients with RA compared
to controls. They contributed this lack of difference to a com-
bination of factors, the most important being that a signiﬁcant
percentage of RA patients did not have inﬂammatory param-
eters at the time of investigation.
In this work, no signiﬁcant correlation was found between
the serum leptin level and disease activity in patients with low,
moderate or high disease activity. This comes in agreement
with the ﬁndings of other studies [14,17,18,25] that reported
no statistical signiﬁcant difference between the leptin level
and disease activity in RA patients. Similarly, Wisolwska
and associates [11] reported that no correlation was found be-
tween DAS-28 score and serum level of leptin. There was no
statistical signiﬁcant difference between median values of lep-
tin level for low and high DAS-28 values.On the contrary, Seven and colleagues [19] found that RA
patients with moderate disease activity (DAS > 2.7) had sig-
niﬁcantly higher leptin levels than those with low disease activ-
ity (DAS < 2.7). Olama and colleagues [26] found that
synovial/serum leptin ratio was signiﬁcantly higher in RA pa-
tients with erosions than RA patients without erosions. Serum
leptin level and synovial/serum leptin ratio signiﬁcantly corre-
lated with RA duration, DAS28, ESR, CRP, TNF-a and IL-6.
These results indicate that local consumption of leptin in the
joint cavity has a protective role against the destructive course
of RA.
In addition, Yoshino and associates [27] reported that ser-
um levels of resistin and leptin were positively associated with
the CRP level in patients with rheumatoid arthritis, suggesting
that these adipokines may act as pro-inﬂammatory cytokines
in this disease. Also, Targojska-Stdpniak and colleagues [20]
found a positive correlation between serum leptin concentra-
tion and DAS-28 values.
In this study, a signiﬁcant positive correlation was found
between serum leptin levels and BMI (P< 0.001) of the RA
patients. Our results come in agreement with the work of other
studies [11,18,24,25,28] that reported a positive correlation
between BMI of RA patients and serum levels of leptin.
Targojska-Stdpniak and colleagues [20] found that leptin con-
centration correlated positively with BMI in women with RA,
but not in men.
On the contrary, Popa and coworkers [4] found that in RA
patients, plasma leptin concentration did not correlate with
BMI. Also, Seven and colleagues [19] reported no correlation
between leptin and BMI. They suggested that regulation of
leptinemia is complex and that weight is not the only major
regulator.
Limitations of this study were the small number of RA
male patients which did not allow us to obtain results of value
to assess the effect of gender on leptin levels. Also, the number
of controls was not gender matched with the patients. Correla-
tion of radiological ﬁndings with leptin levels in the RA
patients was not done; however, it would have added consider-
able information and would be taken into consideration in fur-
ther studies.
In conclusion, circulating leptin levels did not seem to
reﬂect disease activity in our study. Since many aspects of
the biology of leptin remain unclear, we recommend further
research on leptin hormone in relation to other hormonal
changes in rheumatoid arthritis patients, and more studies
on the inﬂuence of leptin on immunity in relation to the met-
abolic state aiming to reach new approaches that may focus on
nutrition for the modulation of the immune response.Conﬂict of interest
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